Menu
Back to Journals » Drug Design, Development and Therapy » Volume 14
Review
A critical review of the United States regulatory pathways for determining the equivalence of efficacy between CT-P13 and original infliximab (Remicade®)
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 6,720 | Dovepress* | 6,216+ | 1,058 | 7,274 | |
| PubMed Central* | 504 | 377 | 881 | ||
| Totals | 6,720 | 1,435 | 8,155 | ||
| *Since 17 July 2020 | |||||
View citations on PubMed Central and Google Scholar